Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Gruppo Italiano Malattie EMatologiche dell'Adulto
OBJECTIVES: Primary * Determine the activity of bcr-abl p210-b3a2 breakpoint-derived pentapeptide vaccine (CMLVAX100), in terms of peripheral blood bcr-abl/abl ratio reduction, in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Secondary * Determine the reduction of molecular residual disease at 3 months in patients treated with this vaccine. * Determine the reduction of molecular residual disease at 12 months in patients treated with maintenance boosts of this vaccine. * Determine the rate of complete molecular response at any time after vaccination. * Determine in vivo and in vitro peptide-specific immune response induced by the vaccine. OUTLINE: This is a prospective, nonrandomized, open-label, multicenter study. Patients receive sargramostim (GM-CSF) subcutaneously (SC) on days 1 and 2 and bcr-abl p210-b3a2 breakpoint-derived pentapeptide vaccine (CMLVAX100) SC on day 2. Treatment repeats every 2 weeks for 6 courses. Patients then receive CMLVAX100 SC once monthly for 3 months and then once every 3 months for 6 months (for a total of 1 year). Patients may receive additional CMLVAX100 SC every 6 months for at least 3 years. Treatment continues in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 69 patients will be accrued for this study.
Age
18–120
Sex
ALL
Healthy volunteers
Not accepted
